PMHNP Specialty Billing
Spravato (Esketamine) Billing for PMHNPs
In-office Spravato has more moving parts than a standard psychiatric visit: a REMS program, a supervised administration and monitoring period, and separate drug and service components. Here is a high-level view of how the billing works and where to verify the specifics.
Why It Is Different
Spravato Is Not a Standard Office Visit
Esketamine, sold as Spravato, is administered in a certified healthcare setting under a federal risk program, and the patient is monitored on site for a required period after each dose. That structure changes the billing. Instead of a single visit code, a Spravato session generally involves a drug component and a separate administration and monitoring component, and it carries requirements, such as prior authorization and specific documentation, that a routine medication management visit does not.
This page gives a plain, high-level overview so a PMHNP practice knows what to plan for. It is not a coding sheet. Because the specifics are money-sensitive and change, we point you to the authorities to confirm them, and it sits alongside our wider PMHNP practice resources, our PMHNP billing and coding overview, and our broader psychiatry and behavioral health billing resources.
Program Context
The REMS Program and In-Office Administration
Spravato is dispensed and administered under a Risk Evaluation and Mitigation Strategy, or REMS, a program required by the FDA for certain medications with safety concerns. In practical terms, the drug is not something a patient picks up and takes at home. It is given in a certified setting, and the practice, prescriber, and pharmacy must be enrolled in the program.
Certified Setting
Administration happens in a healthcare setting enrolled in the REMS program, with the patient self-administering the nasal spray under supervision. Enrollment and program requirements are prerequisites, not billing details, and must be in place first.
Supervised Monitoring Period
After dosing, the patient is monitored on site for a required period, commonly described as around two hours, before being discharged. That monitoring time is a core part of the service and needs to be documented.
Documentation Matters
Because the service is time-bound and safety-driven, records of administration, monitoring, vital signs, and the discharge decision support both patient safety and the claim. Thin documentation is a common source of denials on complex services.
The Components
Separate Drug and Administration Components
The most important billing concept to grasp is that a Spravato session is generally not billed as one line. There is a component for the drug itself and a separate component for administering it and monitoring the patient. Understanding that split, and how each side is handled by a given payer, is the foundation of getting paid correctly.
The Drug Component
The medication is reported using the appropriate drug code and units. The exact code, unit definition, and any required detail vary and change over time, so confirm current requirements with CMS and the specific payer rather than relying on a figure you saw somewhere.
The Administration and Monitoring Component
The in-office administration and the supervised monitoring period are reported separately from the drug. How this is coded, and whether time and supervision requirements apply, is payer-specific. Verify the current definitions with AMA CPT and the payer.
Do Not Rely on Specific Codes Here
We deliberately do not list J-codes, CPT codes, or dollar amounts on this page. They differ by payer and are updated, and using a stale code is a fast route to a denial. Always pull the current values from the authoritative source and the payer for the date of service.
Access and Payment
Prior Authorization and How You Source the Drug
Two operational decisions shape a Spravato program’s economics and cash flow: getting the treatment authorized before you deliver it, and how you obtain and pay for the drug. Both should be settled before your first patient, because both can create large, avoidable financial exposure.
| Consideration | What to Plan For |
|---|---|
| Prior authorization | Spravato commonly requires authorization before administration. Confirm each payer’s requirements and criteria in advance; a missing authorization is often a non-appealable denial. |
| Buy-and-bill | The practice purchases the drug, keeps it in inventory, administers it, and bills the payer. This puts the acquisition cost and reimbursement risk on the practice, so cash flow and denial management matter. |
| Specialty pharmacy | The drug is supplied through a specialty pharmacy for the specific patient, so the practice bills primarily for the administration and monitoring rather than the drug. This shifts drug cost and inventory off the practice. |
| Which model applies | The choice is often driven by the payer and the plan, not solely by preference. Confirm what each payer allows or requires before committing to a sourcing approach. |
| Documentation and units | Whichever path, accurate records of the drug, units, administration, and monitoring time support the claim. Verify current unit and code requirements with CMS, AMA CPT, and the payer. |
Because Spravato sessions are recurring and each one carries authorization, sourcing, and documentation requirements, practices often build dedicated tooling to keep it organized. We build practice operations tooling for exactly this kind of workflow, including esketamine and Spravato tracking, so nothing slips between sessions. The right structure depends on your payers and volume, which is where a practice review helps.
Common Questions
Frequently Asked Questions
How is Spravato billing different from a normal psychiatric visit?
A Spravato session generally has separate drug and administration components rather than a single visit code, includes a required supervised monitoring period that must be documented, and typically involves prior authorization and REMS program participation. It is more operationally involved than routine medication management.
What is the REMS program and why does it matter for billing?
REMS stands for Risk Evaluation and Mitigation Strategy, an FDA-required safety program. Spravato must be administered in a certified setting by enrolled participants, so enrollment and its documentation requirements are prerequisites that underpin a clean, supportable claim.
What codes and amounts should I use for Spravato?
We do not publish specific J-codes, CPT codes, or dollar amounts, because they vary by payer and change over time, and a stale code causes denials. Confirm the current drug code, units, administration coding, and reimbursement with CMS, AMA CPT, and the specific payer for the date of service.
Does Spravato require prior authorization?
It commonly does, but requirements and criteria are set by each payer and plan. Confirm the specific authorization requirements before administering, since a missing or expired authorization is frequently a non-appealable denial that leaves the practice unpaid.
What is the difference between buy-and-bill and specialty pharmacy?
With buy-and-bill, the practice purchases and stocks the drug, administers it, and bills the payer, carrying the acquisition cost and reimbursement risk. With specialty pharmacy, the drug is supplied for a specific patient and the practice mainly bills the administration and monitoring. The payer often dictates which applies.
How much of the monitoring time needs to be documented?
The supervised monitoring after dosing is a core, safety-driven part of the service, so records of administration, monitoring, vital signs, and the discharge decision are important for both patient safety and the claim. Follow the current clinical and payer requirements for what to capture.
Build It Right the First Time
Set Up Your Spravato Program to Get Paid
In-office Spravato rewards practices that plan authorization, sourcing, and documentation before the first session, and it punishes those that improvise. We help PMHNP and behavioral health practices stand up the workflow, verify requirements with the right authorities, and keep each session organized. Start with a practice review.
Informational only, not billing, legal, tax, or medical advice, and not clinical guidance on administering esketamine. Codes, coverage, prior-authorization rules, and reimbursement vary by payer and change over time; confirm all specifics with CMS, AMA CPT, the applicable payer, the manufacturer’s REMS program, and a qualified professional. Last reviewed: July 2026.